Share on facebook
Share on twitter
Share on linkedin

Correction of Haemoglobin Levels in a Heterozygous Humanized Mouse Model of Thalassaemia after Fetal Gene Therapy

Presented at the Neonatal Society 2015 Spring Meeting.

Shangaris P1,2, Loukogeorgakis SP1,3, Subramaniam S1, Blundell M7, Bakhamis N2, Liu S4, Eaton S1, Ramachandra D1, Maghsoudlou P1, Urbani L1, Waddington S2, Archer J5, Antoniou M6, Thrasher AJ7, Ryan T5, De Coppi P1, David A2

1 Surgery Unit, Institute of Child Health, University College London, UK
2 Institute for Women’s Health, Maternal & Fetal Medicine, University College London, UK
3 Center for Fetal Research, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
4 University of Alabama at Birmingham, Birmingham, AL, USA
5 Central Diagnostic Services, Queen’s Vet School Hospital, University of Cambridge, UK
6 Department of Medical and Molecular Genetics, King’s College London, UK
7 Molecular Immunology Unit, Institute of Child Health, UK

Background: Beta thalassaemia is a genetic blood disease that causes life-threatening anemia. Hematopoietic stem cell (HSC) transplantation successfully cures the disease but in only 30% of patients. We hypothesized that in utero gene therapy (IUGT) to the fetal HSC compartment with the corrected beta globin gene might cure the disease before birth.

Methods: A humanized mouse model of thalassaemia (Cooley’s anemia;CA) was used in which heterozygous animals are affected by anaemia, splenomegaly and extra-medullary haematopoiesis. At E13.5 a “GLOBE” vector (HIV-2 based lentiviral vector that incorporates a mini haemoglobin beta gene, the beta-globin promoter and HS2/3β-LCR element) was injected into the liver of each fetus (n=12). At 12 weeks of age, recipient blood, liver, spleen and bone marrow were collected for complete blood count, blood film, as well as RNA and DNA isolation. Extra-medullary haematopoiesis was examined in the spleen and liver using flow cytometry (CD71+/Ter119+cells) and histo-pathological analysis.

Results: Compared to non-injected heterozygous pups (control), IUGT increased haemoglobin levels [11.3±0.4g/dl (n=6) vs. 7.6±0.6g/dl (n=8); p<0.01], red blood cell count [9.3±0.3*1012/L vs. 6.2±0.5*1012/L; p<0.01), and haematocrit [41.2±2.2% vs. 27.2±2.0; p<0.01]. Moreover, treated CA animals had reduced spleen weight [130±5mg vs.310±21mg; p<0.01], as well as reduced extra-medullary haematopoiesis in the liver [0.7±0.1% (n=4) vs. 6.0±0.9% (n=5); p<0.01] and spleen [6.6±1.8 (n=4) vs. 23.1±1.4 (n=3); p<0.05]. qPCR analysis demonstrated increased gene expression of human beta globin and reduced expression of human gamma globin in blood and bone marrow of IUGT offspring. HPLC analysis confirmed these findings at protein level. The average vector copy number in the liver was 0.1.

Conclusion: IUGT resulted in phenotypic normalization in a heterozygous humanized mouse model of CA. Increased levels of beta globin and associated down-regulation of gamma globin is consistent with a switch from fetal to adult human haemoglobin, confirming successful prenatal correction of the genetic defect.

Corresponding author: p.shangaris@ucl.ac.uk

More to explorer

Summer Meeting 2024

19th-21st June 2024 Joint Summer Meeting with the Fetal and Neonatal Physiological Society at University of Nottingham Full 3-day, International Conference |

Spring Meeting 2024

14th March 2024 Hybrid event: Virtual meeting or in person at Royal Society of Medicine, London 09.30 – 18.00 GMT Register Here

Autumn Meeting 2023

9th November 2023 Hybrid event: This will be a hybrid meeting with both in-person attendance at the Royal Society of Medicine, London

Search by category

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.